Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Taxoids | 4 | 2017 | 665 | 1.280 |
Why?
|
Arthralgia | 3 | 2017 | 459 | 1.200 |
Why?
|
Bone Neoplasms | 7 | 2020 | 2567 | 1.050 |
Why?
|
Antiemetics | 5 | 2019 | 185 | 0.930 |
Why?
|
Nausea | 5 | 2019 | 680 | 0.840 |
Why?
|
Vomiting | 5 | 2019 | 647 | 0.830 |
Why?
|
Gastric Inhibitory Polypeptide | 1 | 2022 | 69 | 0.780 |
Why?
|
Antihypertensive Agents | 6 | 2022 | 2033 | 0.720 |
Why?
|
Hypertension | 7 | 2022 | 8626 | 0.710 |
Why?
|
Palliative Care | 6 | 2020 | 3645 | 0.540 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 969 | 0.480 |
Why?
|
Blood Pressure | 6 | 2022 | 8532 | 0.460 |
Why?
|
Education | 1 | 2015 | 533 | 0.410 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 616 | 0.400 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2022 | 12240 | 0.390 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2021 | 2310 | 0.370 |
Why?
|
Glomerular Filtration Rate | 2 | 2021 | 2233 | 0.370 |
Why?
|
Cardiology | 1 | 2022 | 1702 | 0.370 |
Why?
|
Health Expenditures | 2 | 2022 | 2387 | 0.360 |
Why?
|
Pain Measurement | 3 | 2017 | 3561 | 0.320 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5891 | 0.320 |
Why?
|
Life Expectancy | 1 | 2015 | 1247 | 0.300 |
Why?
|
Insulin | 1 | 2022 | 6599 | 0.290 |
Why?
|
Medicare | 2 | 2022 | 6823 | 0.280 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 3685 | 0.270 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1085 | 0.260 |
Why?
|
Benzodiazepines | 3 | 2016 | 1136 | 0.250 |
Why?
|
Pain | 2 | 2015 | 5077 | 0.220 |
Why?
|
Models, Theoretical | 1 | 2015 | 3564 | 0.210 |
Why?
|
Parenteral Nutrition | 2 | 2019 | 660 | 0.210 |
Why?
|
Curriculum | 1 | 2015 | 3782 | 0.190 |
Why?
|
Famotidine | 1 | 2021 | 17 | 0.190 |
Why?
|
Enteral Nutrition | 2 | 2019 | 803 | 0.190 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15651 | 0.180 |
Why?
|
Incretins | 1 | 2021 | 100 | 0.180 |
Why?
|
Colchicine | 1 | 2021 | 256 | 0.170 |
Why?
|
Naphthyridines | 1 | 2022 | 182 | 0.170 |
Why?
|
Humans | 49 | 2023 | 765956 | 0.170 |
Why?
|
Serotonin 5-HT3 Receptor Antagonists | 2 | 2019 | 23 | 0.170 |
Why?
|
United States | 13 | 2023 | 72898 | 0.170 |
Why?
|
Glucagon-Like Peptides | 1 | 2021 | 157 | 0.170 |
Why?
|
Clinical Competence | 1 | 2015 | 4863 | 0.170 |
Why?
|
Brain Neoplasms | 3 | 2016 | 9071 | 0.160 |
Why?
|
Neoplasms | 8 | 2019 | 22340 | 0.160 |
Why?
|
Rural Health | 1 | 2021 | 301 | 0.160 |
Why?
|
Hypotension, Orthostatic | 1 | 2022 | 257 | 0.160 |
Why?
|
Pulmonary Edema | 1 | 2022 | 412 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 530 | 0.150 |
Why?
|
Albuminuria | 1 | 2022 | 660 | 0.150 |
Why?
|
Awards and Prizes | 1 | 2022 | 364 | 0.150 |
Why?
|
Radiosurgery | 2 | 2019 | 1328 | 0.150 |
Why?
|
Anti-Obesity Agents | 1 | 2021 | 242 | 0.150 |
Why?
|
American Heart Association | 1 | 2022 | 1047 | 0.140 |
Why?
|
Patient Admission | 2 | 2021 | 1365 | 0.130 |
Why?
|
Patient Care | 1 | 2022 | 629 | 0.130 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 3251 | 0.130 |
Why?
|
Breast Neoplasms | 3 | 2017 | 21056 | 0.120 |
Why?
|
Prevalence | 6 | 2021 | 15839 | 0.120 |
Why?
|
Ondansetron | 1 | 2016 | 95 | 0.120 |
Why?
|
Antineoplastic Agents | 5 | 2019 | 13648 | 0.120 |
Why?
|
Protein-Energy Malnutrition | 1 | 2016 | 189 | 0.120 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 445 | 0.120 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2020 | 1237 | 0.110 |
Why?
|
Drug Approval | 1 | 2021 | 818 | 0.110 |
Why?
|
Quality of Life | 6 | 2017 | 13461 | 0.110 |
Why?
|
Methylprednisolone | 1 | 2016 | 386 | 0.110 |
Why?
|
Aged | 15 | 2022 | 171114 | 0.110 |
Why?
|
Prognosis | 5 | 2019 | 29921 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1472 | 0.110 |
Why?
|
Diabetes Complications | 1 | 2020 | 1316 | 0.110 |
Why?
|
Retreatment | 1 | 2015 | 598 | 0.110 |
Why?
|
Cholesterol, LDL | 1 | 2023 | 2393 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2021 | 10383 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1672 | 0.100 |
Why?
|
Hypoglycemic Agents | 2 | 2022 | 3110 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20660 | 0.100 |
Why?
|
Heart Failure | 3 | 2022 | 11840 | 0.100 |
Why?
|
Cause of Death | 2 | 2021 | 3708 | 0.100 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 3925 | 0.100 |
Why?
|
Bone Remodeling | 1 | 2015 | 577 | 0.100 |
Why?
|
Middle Aged | 18 | 2021 | 223004 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3800 | 0.090 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 1731 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1880 | 0.080 |
Why?
|
Obesity | 2 | 2022 | 13075 | 0.080 |
Why?
|
Nutrition Surveys | 3 | 2022 | 1741 | 0.080 |
Why?
|
Female | 21 | 2021 | 396101 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2021 | 3050 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 8041 | 0.080 |
Why?
|
Cohort Studies | 2 | 2022 | 41647 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2021 | 59488 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1494 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3888 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 1927 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3412 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2020 | 2770 | 0.070 |
Why?
|
Dexamethasone | 1 | 2016 | 1963 | 0.070 |
Why?
|
Male | 19 | 2021 | 363691 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15880 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2021 | 5343 | 0.070 |
Why?
|
Radiation Dosage | 1 | 2015 | 1944 | 0.070 |
Why?
|
Risk Factors | 4 | 2023 | 74836 | 0.070 |
Why?
|
Adult | 12 | 2023 | 223038 | 0.060 |
Why?
|
Survival Rate | 1 | 2019 | 12795 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2023 | 6546 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2015 | 3074 | 0.050 |
Why?
|
Registries | 1 | 2018 | 8297 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10808 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2021 | 65189 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 3181 | 0.040 |
Why?
|
Time Factors | 2 | 2019 | 40065 | 0.040 |
Why?
|
Histamine H2 Antagonists | 1 | 2021 | 168 | 0.040 |
Why?
|
Hospitals, Rural | 1 | 2021 | 175 | 0.040 |
Why?
|
Risk | 2 | 2021 | 9591 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 493 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 4274 | 0.040 |
Why?
|
Incidence | 1 | 2017 | 21480 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2012 | 3967 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2020 | 245 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9649 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2020 | 81515 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2021 | 423 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39194 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5389 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4893 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2023 | 1811 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2021 | 1158 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11868 | 0.030 |
Why?
|
Prospective Studies | 2 | 2017 | 54806 | 0.030 |
Why?
|
Dyssomnias | 1 | 2015 | 28 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2022 | 1315 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12509 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 591 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1207 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1013 | 0.030 |
Why?
|
Needs Assessment | 1 | 2020 | 1138 | 0.030 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.030 |
Why?
|
Drug Utilization | 1 | 2020 | 1187 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 647 | 0.030 |
Why?
|
Nutritional Support | 1 | 2016 | 178 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1885 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11083 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 1217 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2021 | 1406 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 163 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6069 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2018 | 2910 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13451 | 0.020 |
Why?
|
Nutritional Status | 1 | 2019 | 1620 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6919 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2709 | 0.020 |
Why?
|
Paclitaxel | 1 | 2017 | 1728 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2411 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2904 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2699 | 0.020 |
Why?
|
Ultrasonography | 1 | 2022 | 5993 | 0.020 |
Why?
|
Infection Control | 1 | 2016 | 983 | 0.020 |
Why?
|
Fatigue | 1 | 2015 | 1549 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4850 | 0.020 |
Why?
|
Weight Loss | 1 | 2019 | 2710 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2680 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20125 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4058 | 0.020 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2184 | 0.010 |
Why?
|
Body Mass Index | 1 | 2022 | 13039 | 0.010 |
Why?
|
Animals | 1 | 2016 | 168759 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6203 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10602 | 0.010 |
Why?
|
Lung | 1 | 2022 | 10033 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5506 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10563 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18380 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26313 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7836 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11501 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 24283 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13631 | 0.010 |
Why?
|
Stroke | 1 | 2018 | 9747 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 59886 | 0.010 |
Why?
|
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_